FDA 483 - Lupin Limited - April 07, 2017

The FDA Form 483 document details significant deficiencies in a pharmaceutical firm's quality control and manufacturing processes from January 2015 to March 2017.

**Key Violations and Observations:**

* **Inadequate Out-of-Specification (OOS) Investigations:** The firm repeatedly failed to thoroughly review unexplained discrepancies and OOS results. Several initial OOS results were invalidated through re-testing without reaching assignable causes or implementing appropriate corrective and preventative actions (CAPAs). * For example, OOS investigations for Tablets, mg (Batch ) and Tablets, USP mg (Batch ) attributed failures to evaporated sample solvent but lacked CAPAs to prevent recurrence. * OOS for USP, Batch (API testing) was invalidated as an outlier without an assignable cause. * Content Uniformity failures for Tablets, mg (Batches and ) were attributed to "improper rinsing of shaft" based on assumption, not scientific evaluation, and manufacturing processes were not reviewed. * An Out-of-Trend (OOT) investigation for Tablets, mg (Batch ) concluded "improper of the sample" without reviewing the manufacturing process despite increasing variability. * API Particle Size OOS for USP, Batch was invalidated without adequate investigation, citing "probably due to or sampling handling" without conclusive evidence.

* **Deficient Laboratory Analyst Training:** Training for laboratory analysts regarding investigations purportedly caused by laboratory